

# Oversight for All: Achieve data transparency with elluminate

Jason Konn  
Senior Solutions Consultant  
eClinicalSolutions

By a show of hands...

How many of you know where  
all of your clinical and  
operational data is stored?

Keep them raised if you also  
know who can access this data.

Now, keep your hand up if  
you're confident you can derive  
value from this data.



# Data Transparency

Data Transparency = Availability.

Intuitive


Accessible

User-friendly



	A	B	C	D	E	F	G
	OrderDate	Region	Rep	Item	Units	Unit Cost	Total
1	1/6/15	East	Jones	Pencil	95	1.99	189.05
2	1/23/15	Central	Kivell	Binder	50	19.99	999.50
3	2/9/15	Central	Jardine	Pencil	36	4.99	179.64
4	2/26/15	Central	Gill	Pen	27	19.99	539.73
5	3/15/15	West	Sorvino	Pencil	56	2.99	167.44
6	4/1/15	East	Jones	Binder	60	4.99	299.40
7	4/18/15	Central	Andrews	Pencil	75	1.99	149.25
8	5/5/15	Central	Jardine	Pencil	90	4.99	449.10
9							

```
{
  "trackid": "AA-1234",
  "reported_dt": "12/31/2019 23:59:59",
  "longitude": -111.12500000,
  "latitude": 33.37500000
},
{
  "trackid": "BB-7890",
  "reported_dt": "12/31/2019 23:59:59",
  "longitude": -113.67500000,
  "latitude": 35.87500000
},
{
  "trackid": "CC-4545",
  "reported_dt": "12/31/2019 23:59:59",
  "longitude": -115.57500000,
  "latitude": 37.67500000
}
```



PROTOCOL NO. MA-CT-10-002		SITE ID 001	SUBJECT INITIALS A-I
SCREENING (V1 / -14 to -1 days)			
Does the subject have any past or ongoing medical / surgical history?			
Description	Start Date (dd / mmm / yyyy)	Stop Date (dd / mmm / yyyy)	
Type II Diabetes Mellitus	UK/UK/11/9/90	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No If "Yes", please	
Hypertension	UK/UK/11/9/95	Stop Date	
Underwent Surgery for Kidney Stones	UK/UK/12/0/7	UK/UK/12/0/7	




# Data Transparency

Data Transparency = Visualization.

simple

Interactive

Engaging



# Data Transparency

Data Transparency = Integration.

Unified

Consolidated

Streamlined

PatientID	Age	Gender	EnrollmentDate	Condition
P1000	60	Male	2023-06-02 18:54:39	Condition B
P1001	54	Male	2023-09-08 18:54:39	Condition B
P1002	31	Male	2024-02-28 18:54:39	Condition A
P1003	36	Male	2023-08-19 18:54:39	Condition A
P1004	36	Female	2023-06-04 18:54:39	Condition B
P1005	46	Female	2024-02-28 18:54:39	Condition A
P1006	59	Other	2023-07-24 18:54:39	Condition B

PatientID	Medication	Dose	AdministrationDate	SideEffects
P1000	Medication C	20mg	2023-06-04 18:54:39	Moderate
P1000	Medication C	10mg	2023-09-19 18:54:39	Moderate
P1000	Medication C	20mg	2023-09-21 18:54:39	Severe
P1001	Medication A	20mg	2024-03-20 18:54:39	Severe
P1001	Medication B	50mg	2024-03-10 18:54:39	Moderate
P1001	Medication C	50mg	2023-04-10 18:54:39	Mild
P1002	Medication C	20mg	2023-08-09 18:54:39	Mild

TrialPhase	StartDate	EndDate	#OfParts	SuccessRate
Phase 1	2023-04-02 18:54:39	2024-06-30 18:54:39	33	75.07985837
Phase 2	2023-07-06 18:54:39	2024-09-28 18:54:39	92	85.97183308
Phase 3	2023-10-04 18:54:39	2024-12-27 18:54:39	61	78.91325943
Phase 4	2024-01-02 18:54:39	2025-04-01 18:54:39	90	80.15276633

PatientID	Medication	Dose	AdministrationDate	SideEffects	Age	Gender	EnrollmentDate	Condition
P1000	Medication C	20mg	2023-06-04 18:54:39	Moderate	60	Male	2023-06-02 18:54:39	Condition B
P1000	Medication C	10mg	2023-09-19 18:54:39	Moderate	60	Male	2023-06-02 18:54:39	Condition B
P1000	Medication C	20mg	2023-09-21 18:54:39	Severe	60	Male	2023-06-02 18:54:39	Condition B
P1001	Medication A	20mg	2024-03-20 18:54:39	Severe	54	Male	2023-09-08 18:54:39	Condition B
P1001	Medication B	50mg	2024-03-10 18:54:39	Moderate	54	Male	2023-09-08 18:54:39	Condition B
P1001	Medication C	50mg	2023-04-10 18:54:39	Mild	54	Male	2023-09-08 18:54:39	Condition B
P1002	Medication C	20mg	2023-08-09 18:54:39	Mild	31	Male	2024-02-28 18:54:39	Condition A
P1002	Medication B	50mg	2024-01-23 18:54:39	Moderate	31	Male	2024-02-28 18:54:39	Condition A
P1002	Medication B	20mg	2024-03-18 18:54:39	None	31	Male	2024-02-28 18:54:39	Condition A
P1003	Medication A	10mg	2023-11-27 18:54:39	Moderate	36	Male	2023-08-19 18:54:39	Condition A
P1003	Medication C	50mg	2024-01-21 18:54:39	None	36	Male	2023-08-19 18:54:39	Condition A
P1003	Medication C	10mg	2024-02-25 18:54:39	Mild	36	Male	2023-08-19 18:54:39	Condition A

# Product Demo



# eClinical Solutions: ellumiante Analytics

Elluminate allows your Clinical and Operational Data to be...

## Available

- SaaS
- Refreshed Daily
- Permission Based

## Visual

- 50+ out of the box reports
- Interactive
- Create 'issues'

## Integrated

- Cross Study Analytics
- Labs, AEs, ConMed, etc.
- Source Agnostic



# Thank You!

[eclinicalsol.com](http://eclinicalsol.com)  
[877.355.8668 \(877-ELLUMN8\)](tel:877.355.8668)  
[info@eclinicalsol.com](mailto:info@eclinicalsol.com)



Connect with Us!





# Appendix



Adverse Event Summary

Create IssueIssuesRegister ReviewReviewsCopy LinkShareHelp Center

Study

Site

Subject

Country

Group Assignment

Special Interest AE

Treatment Emergent

Subject Counts

Event Counts

System Organ Class

High Level Group ...

High Level Term

Preferred Term

Reported Term

Toxicity

Highest Tox...

Seriousness




Action Taken

Outcome

Causality

AE Duration

Group Assi...



Unique Subject Identifier	Study	Site	Subject ID	Country	Age	Sex	Reported Term for the Adverse Event
CLINTEK-006-0001-002	CLINTEK-006	0001	0001-002	USA	78	Female	ANEMIA
CLINTEK-006-0001-002	CLINTEK-006	0001	0001-002	USA	78	Female	ANOREXIA
CLINTEK-006-0001-002	CLINTEK-006	0001	0001-002	USA	78	Female	DIFFICULTY HEARIN
CLINTEK-006-0001-002	CLINTEK-006	0001	0001-002	USA	78	Female	EASY BLEEDING
CLINTEK-006-0001-002	CLINTEK-006	0001	0001-002	USA	78	Female	EASY BRUISING
CLINTEK-006-0001-002	CLINTEK-006	0001	0001-002	USA	78	Female	ECCHYMOSIS ON LE FACE, RIGHT ARM AT SIDE OF BODY
CLINTEK-006-0001-002	CLINTEK-006	0001	0001-002	USA	78	Female	ELEVATED ALKALINE PHOSPHATASE



Enrollment Summary

Create IssueIssuesRegister ReviewReviewsCopy LinkShareHelp Center

Study

Country

Site

Status

Group Assignment

Sites

16<sup>6</sup> Countries

Total Planned Enrollment

Please select a single Study

Subjects Screened



137<sup>120</sup> Enrolled Subjects

Screen Failure Rate

12.4%

Days Since Last Patient Screened

381



Study	Country	Site Number	Site	# of Subjects Screened	# of Eligible	# of Consented	# of Enrolled	Enrollment Rate	# of Treated	Treated Rate	# of Screen Failures	Screen Failure Rate	# of Days Since Last Patient Screened	Active
eCS-DS-001	India	0004	Sacred Heart Medical Center	4	2	4	2	50.00%	2	50.00%	2	50.00%	727	Y
eCS-DS-001	United Kingdom	0005	Addenbrookes Hospital	4	2	4	2	50.00%	2	50.00%	2	50.00%	644	Y
eCS-DS-001	Spain	0006	Hospital Virgen Macarena	4	2	4	2	50.00%	2	50.00%	2	50.00%	594	Y
eCS-DS-001	Canada	0007	Canadian Institutes of Health Research (CIHR)	3	2	3	2	66.67%	2	66.67%	1	33.33%	549	Y
eCS-DS-001	United States of America	0008	Mayo Clinic	5	3	5	3	60.00%	3	60.00%	2	40.00%	685	Y

# Queries Duration

Create Issue Issues Register Review Reviews Copy Link Share Help Center

Study Site Country Sender-Recipient Query Type

Average Days Outstanding (>=)

Avg Days Outstanding

1,465.4

Avg Days Open to Answered

21.6


Avg Days Answered to Closed

17.3


Avg Days Open to Closed

38.3


## Outstanding (Currently Opened Queries)




## Open to Answered



## Answered to Closed



## Open to Closed



## Labs Summary

[Create Issue](#)
[Issues](#)
[Register Review](#)
[Reviews](#)
[Copy Link](#)
[Share](#)
[Help Center](#)

Study

Subject

Category for Lab Test

Test

Study Period

nxULN Range

Average

Visit Name

Vendor N...

Group Ass...

Site


Sex

Toxicity

Group Assignment

Low Normal High

0-0.2 0.2-0.4 0.4-0.6 0.6-0.8 0.8-1.0 1-1.3 1.3-3 3-5 5-7 7-9 >9



### Lab Numerical Results by Visit Name

	Test	Subject	Visit Name										
			UNUSCHEDULED 0.01	Screening	UNUSCHEDULED 1.01	UNUSCHEDULED 1.02	Screening - Visit 2	UNUSCHEDULED 2.01	UNUSCHEDULED 2.02	C1D1	UNUSCHEDULED 3.01	Run-in Visit 2	UNUSCHEDULED 4.01
+ Basophils/Leukocytes (<missing>)	-	0.052	0.000	-	0.006	0.000	-	0.071	0.000	0.070	0.006		
+ Basophils/Leukocytes (x10^9/L)	-	0.195	-	-	-	-	-	0.127	-	-	-	-	
+ Beta-2 Microglobulin (<missing>)	-	-	-	-	-	-	-	1.000	-	-	-	-	
+ Beta-2 Microglobulin (mg/L)	-	-	-	-	-	-	-	9.063	-	-	-	-	
+ Bicarbonate (<missing>)	-	25.080	-	-	-	-	-	26.720	-	25.000	-	-	
+ Bicarbonate (mmol/L)	-	-	26.667	-	25.814	25.050	31.000	24.713	-	-	-	-	
+ Bilirubin (<missing>)	-	-	-	-	1.000	-	-	1.000	-	-	-	-	
+ Bilirubin (umol/L)	-	25.342	25.009	-	29.471	4.850	10.260	27.559	-	17.100	-	-	
+ Blasts/Leukocytes (<missing>)	-	5.860	-	-	-	-	-	-	-	-	-	-	
+ Blood Urea Nitrogen (mmol/L)	-	-	6.783	-	6.519	6.480	6.069	6.338	-	-	-	-	
+ C Reactive Protein (<missing>)	-	4.388	-	-	-	-	-	4.724	-	2.185	-	-	
+ C Reactive Protein (mg/L)	-	-	-	-	69.989	-	-	39.537	-	-	-	-	
+ Calcium (<missing>)	-	-	-	-	-	-	-	-	-	-	-	-	
+ Calcium (mmol/L)	-	2.388	2.150	-	2.269	2.242	-	2.254	-	2.096	-	-	
+ Cellular Casts (/LPF)	-	-	-	-	1.200	-	-	7.000	-	-	-	-	
+ Cellular Casts (/lpf)	-	-	0.000	-	0.827	-	-	1.130	-	-	-	-	
+ Chloride (<missing>)	-	-	-	-	-	-	-	-	-	-	-	-	
+ Chloride (mmol/L)	-	98.083	101.333	-	101.487	98.000	101.000	101.813	-	103.000	-	-	
+ Creatine Kinase (<missing>)	-	128.966	-	-	-	-	-	112.680	-	200.000	-	-	
+ Creatine Kinase (U/L)	-	-	0.001	-	0.707	0.701	-	0.715	-	-	-	-	